Dr. Roujun Peng 彭柔君
Chief Physician, Associate Professor
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology with a focus on breast cancer treatment, including chemotherapy and targeted therapy.
Dr. Peng has worked in the Department of Medical Oncology at Sun Yat-sen University Cancer Center since 2000. Dr. Peng earned a medical degree from Sun Yat-sen University of Medical Sciences (2000), a master’s (2007) and PhD (2011) from Sun Yat-sen University, and completed joint doctoral training at Karolinska Institutet, Sweden (2008–2010). Research focuses on anticancer drugs. Dr. Peng has led or participated in three National Natural Science Foundation projects, one National 863 Program project, and eight provincial or institutional grants.
Professional roles
- Chair, First Committee of the Comprehensive Tumor Treatment Branch, Guangdong Precision Medicine Application Society
- Standing Committee Member, First Branch of Tumor Precision Diagnosis and Treatment, Guangdong Medical Association
- Standing Committee Member, Gynecologic Oncology Expert Committee, Guangdong Pharmaceutical Association
- Secretary, First Committee of the South China Breast Cancer Clinical Research Collaboration Group
Name order: in Chinese the family name comes first (Peng Roujun). Papers usually list the name as Roujun Peng or Peng R.
Selected publications
54 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Heliyon, 2024 (senior author): Bioinformatics analysis of MMP14+ myeloid cells affecting endothelial-mesenchymal transformation and immune microenvironment in glioma. PubMed 38434278
- Clin Exp Med, 2023 (senior author): Characteristics and classification of first primary cancer patients with second primary cancer: a population-based cohort study. PubMed 37555912
- J Clin Med, 2023 (senior author): New Staging System and Prognostic Model for Malignant Phyllodes Tumor Patients without Distant Metastasis: A Development and Validation Study. PubMed 36902676
- Front Genet, 2022 (senior author): An immune and epithelial-mesenchymal transition-related risk model and immunotherapy strategy for grade II and III gliomas. PubMed 36778912
- Front Genet, 2022 (senior author): Pan-cancer analysis identifies DDX56 as a prognostic biomarker associated with immune infiltration and drug sensitivity. PubMed 36568395
- Ann Transl Med, 2022 (senior author): Development and validation of a prognostic model and gene co-expression networks for breast carcinoma based on scRNA-seq and bulk-seq data. PubMed 36660733
- J Oncol, 2020 (senior author): Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China. PubMed 33061970
- Leukemia, 2019 (first author): Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. PubMed 30546078
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion